# ALMR (Alamar Biosciences, Inc.) - SEC EDGAR Financial Statements

> Alamar Biosciences, Inc. reported $378.0M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ALMR
- Markdown: https://convexityos.com/fundamentals/ALMR.md
- SEC CIK: 0002104204
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:22 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002104204&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $226.6M | Total debt: $42.35M |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $33.55M | $29.43M | $26.04M | $19.91M | $16.16M | $13.09M |
| Cost of Revenue | $12.90M | $11.71M | $11.58M | $8.02M | $7.58M | $6.70M |
| **Gross Profit** | $20.64M | $17.72M | $14.46M | $11.90M | $8.58M | $6.39M |
| Research & Development | $16.17M | $13.82M | $13.02M | $10.21M | $8.89M | $8.30M |
| Selling, General & Admin | $19.62M | $17.43M | $13.79M | $9.58M | $7.61M | $6.64M |
| Total Operating Expenses | $35.78M | $31.25M | $26.80M | $19.78M | $16.50M | $14.94M |
| **Operating Income** | -$15.14M | -$13.53M | -$12.35M | -$7.88M | -$7.92M | -$8.55M |
| **EBITDA** | -$13.71M | -$12.40M | -$11.18M | -$6.90M | -$7.00M | -$7.67M |
| Interest Income | $2.17M | $1.88M | $539K | $410K | $630K | $786K |
| Income Before Tax | -$13.25M | -$13.29M | -$20.86M | -$7.56M | -$7.02M | -$7.66M |
| Income Tax Expense | $94K | -$93K | $464K | $440K | -- | -- |
| **Net Income** | -$13.34M | -$13.20M | -$21.32M | -$8.00M | -$7.02M | -$7.66M |
| Basic EPS | -$0.19 | -$0.22 | -$1.74 | -$0.69 | -$0.62 | -$0.68 |
| **Diluted EPS** | -$0.19 | -$0.22 | -$1.74 | -$0.69 | -$0.62 | -$0.68 |
| Basic Shares Outstanding | 69.1M | 58.7M | 12.3M | 11.6M | 11.4M | 11.3M |
| Diluted Shares Outstanding | 69.1M | 58.7M | 12.3M | 11.6M | 11.4M | 11.3M |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $121.5M | $133.0M | $64.59M | $30.00M |
| Short-Term Investments | $105.1M | $117.1M | $0 | $0 |
| **Cash & Short-Term Investments** | $226.6M | $250.1M | $64.59M | $30.00M |
| Accounts Receivable, Net | $21.61M | $20.34M | $19.52M | $12.75M |
| Inventory | $54.13M | $45.41M | $39.93M | $38.48M |
| **Total Current Assets** | $317.7M | $331.4M | $141.5M | $94.70M |
| Property, Plant & Equipment, Net | $15.24M | $13.36M | $10.47M | $10.50M |
| Long-Term Investments | -- | -- | $0 | $0 |
| Other Non-Current Assets | $2.51M | $2.58M | $2.09M | $1.76M |
| **Total Non-Current Assets** | $60.34M | $59.59M | $44.98M | $45.29M |
| **Total Assets** | $378.0M | $391.0M | $186.5M | $140.0M |
| Accounts Payable | $16.55M | $13.79M | $5.63M | $5.87M |
| Deferred Revenue (Current) | $1.78M | $2.19M | $2.11M | $470K |
| **Total Current Liabilities** | $33.48M | $27.96M | $24.05M | $23.73M |
| Other Non-Current Liabilities | $974K | $1.03M | $1.20M | $599K |
| **Total Non-Current Liabilities** | $40.84M | $50.16M | $105.5M | $40.22M |
| **Total Liabilities** | $74.32M | $78.12M | $129.5M | $63.95M |
| **Total Debt (incl. Leases)** | $42.35M | $41.46M | $30.58M | $31.66M |
| Common Stock | $7.0K | $7.0K | $1.0K | $1.0K |
| Retained Earnings | -$216.6M | -$203.3M | -$190.1M | -$168.8M |
| Accumulated Other Comp. Income | -$173K | -$139K | -$80K | -$72K |
| **Total Stockholders' Equity** | $303.7M | $312.9M | -$178.1M | -$159.0M |
| Total Equity | $303.7M | -$312.9M | -$178.1M | -$159.0M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$13.34M | -$13.20M | -$21.32M | -$8.00M | -$7.02M | -$7.66M |
| Depreciation & Amortization | $1.42M | $1.13M | $1.17M | $983K | $919K | $888K |
| Stock-Based Compensation | $3.92M | $3.28M | $1.47M | $705K | $680K | $619K |
| Change in Receivables | -$1.32M | -$967K | -$6.85M | -$956K | -$2.32M | -$533K |
| Change in Inventory | -$10.21M | -$5.72M | -$1.26M | -$9.44M | -$7.06M | -$2.36M |
| Change in Payables | $1.63M | $6.32M | $1.34M | $3.22M | -$1.81M | $578K |
| **Operating Cash Flow** | -$14.73M | -$11.32M | -$20.35M | -$14.14M | -$11.88M | -$13.07M |
| Capital Expenditure | -$463K | -$3.64M | -$600K | -$1.22M | -$753K | -$554K |
| **Free Cash Flow** | -$15.20M | -$14.96M | -$20.95M | -$15.36M | -$12.63M | -$13.62M |
| **Investing Cash Flow** | $11.74M | -$120.8M | -$778K | $14.19M | $17.95M | $17.02M |
| **Financing Cash Flow** | -$9.85M | $201.8M | $55.76M | $10.40M | $164K | $243K |
| **Net Change in Cash** | -$12.78M | $69.73M | $34.58M | $9.98M | $6.56M | $4.33M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 9.49x | 11.85x | 5.88x | -- | -- | -- |
| Quick Ratio | 7.87x | 10.23x | 4.22x | -- | -- | -- |
| Debt to Equity | 0.14x | 0.13x | -- | -- | -- | -- |
| **Revenue Growth (YoY)** | +68.5% | +82.1% | +98.9% | -- | -- | -- |
| Gross Profit Growth (YoY) | +73.5% | +106.5% | +126.3% | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
